In conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) ≥30 kg/m2, or overweight patients (BMI ≥28 kg/m2) with associated risk factors eg, type II diabetes, hyperlipidemia and hypertension. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to loose at least 5% of their body weight as measured at the start of drug therapy.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
